Investitionsthese
CARB-X accelerates global antibacterial innovation by funding the development of new antibiotics and other life-saving products to combat drug-resistant bacteria, ensuring these treatments are available worldwide.
Investitionsphase
Early development to advanced development (clinical trials)
Bevorzugte Reifephase für die erste Finanzierung.
Sektoren & Themen
Antibacterial innovation, novel antibiotics, diagnostics, preventatives, and life-saving products against drug-resistant bacteria
Thematische Schwerpunkte und Zielmarktsegmente von Interesse.
Ticketgröße
k.A.
Standard-Finanzierungsbetrag pro Runde.
Outreach & Dossier-Analysen
Verifiziertes E-Mail-Muster
Analysen-Scorecard der Investitionsthese
Unser KI-Analyzer hat Portfolio-Unternehmen gescannt und verifizierte Übereinstimmungen berechnet...
Investment Team (10)
B
Beth Amiott
Alliance Director
B
Betsy Wonderly Trainor
Alliance Director
D
Damiano de Felice
Chief of External Affairs
D
Daniel Burgess
Chair of the CARB-X Joint Oversight Board
E
Ed Buurman
Alliance Director
E
Erin Duffy
Chief of Research & Development
K
Kevin Outterson
Executive Director
R
Richard Alm
Interim Chief of Research and Development
T
Trudy Grossman
Alliance Director
V
Vega Masignani
Alliance Director